Glaucoma News and Research

Latest Glaucoma News and Research

Chronic hypertension increases glaucoma risk

A new study published in Investigative Ophthalmology & Visual Science has found that chronic (long term) hypertension increases a person's susceptibility to glaucoma. These results suggest that doctors should consider a patient's blood pressure levels in managing the potentially blinding eye disorder.

6 Jan 2015

Prostaglandin analogue eye drops reduce risk of vision loss in OAG patients

Prostaglandin analogue eye drops, the most commonly prescribed treatment for glaucoma, can greatly reduce risk of vision loss in people with open angle glaucoma (OAG), one of the leading causes of blindness, according to the first placebo-controlled trial to assess their vision-preserving effect published in The Lancet.

22 Dec 2014

IRIDEX's China distributor secures large tender to supply ophthalmology laser equipment

IRIDEX Corporation (Nasdaq: IRIX) announced today that its China distributor has been awarded a competitive tender for more than $620,000 in ophthalmology laser equipment to fulfill a government program designed to provide advanced ophthalmology solutions to patients across vast areas of China's rural regions.

2 Dec 2014

Eylea receives Health Canada approval for treatment of CRVO and DME

Bayer Inc. announced today that it has received approval from Health Canada for Eylea (aflibercept, solution for intravitreal injection) for the treatment of diabetic macular edema (DME). This new indication comes just six weeks following the October 16th approval of Eylea for the treatment of visual impairment due to macular edema secondary to central retinal vein occlusion (CRVO).

1 Dec 2014

Understanding the genetic basis of glaucoma

Scientists from the University of Liverpool have sequenced the mitochondrial genome in glaucoma patients to help further understanding into the genetic basis for the disease.

16 Nov 2014

Eye screenings of underserved populations reveal one in five has early stage diabetic retinopathy

Eye screenings of people with diabetes in underserved communities revealed that one in five had early stage diabetic retinopathy, according to a new study by a research consortium including investigators at the University of Alabama at Birmingham.

13 Nov 2014

Leading causes of blindness can be detected by looking at how eyes respond to watching TV

One of the leading causes of blindness worldwide could be detected by how our eyes respond to watching TV according to a new study from researchers at City University London.

11 Nov 2014

Endothelin gene expression linked to vision loss in premature babies

A gene known to play a major role in constricting blood vessels also appears to be a major player in the aberrant blood vessel growth that can destroy the vision of premature babies.

11 Nov 2014

Hemp Health launches CBD wellness supplements

Hemp Health Inc., a pioneer in hemp cannabidiol (CBD) products, today launched their line of CBD wellness supplements. Available in oil, spray and capsule form, Hemp Health's products offer a compelling alternative to medical marijuana. The CBD supplements provide consumers with the therapeutic ingredient in hemp while allowing them to avoid the negative mental and physical effects of marijuana.

4 Nov 2014

Tablet screening app can improve eye health outcomes in remote, underserved communities

Using a tablet screening app could prove to be an effective method to aid in the effort to reduce the incidence of avoidable blindness in populations at high-risk for glaucoma with limited access to health care, according to a study released today at AAO 2014, the 118th annual meeting of the American Academy of Ophthalmology.

21 Oct 2014

IRIDEX to host Speakers' Forum program at the American Academy of Ophthalmology

IRIDEX Corporation (Nasdaq: IRIX) announced today its Speakers' Forum program at the annual meeting of the American Academy of Ophthalmology to be held on October 18 – 21 at McCormick Place in Chicago.

17 Oct 2014

Consultant Live unveils new online sleep disorders educational program for doctors, nurses

UBM Medica US announces that Consultant Live a leading online community for primary care clinicians, has unveiled a new online sleep disorders educational program to help doctors and nurses help their patients get a good night's rest.

14 Oct 2014

IRIDEX's new proprietary disposable delivery device granted U.S. patent

IRIDEX Corporation today announced that the United States Patent and Trademark Office granted the company a patent for a new proprietary disposable delivery device.

7 Oct 2014

Bausch + Lomb’s sub-micron loteprednol etabonate ophthalmic gel meets primary endpoint

Bausch + Lomb, a wholly owned subsidiary of Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX), today announced that its next generation sub-micron gel formulation of loteprednol etabonate was statistically superior to placebo (vehicle gel) in eliminating inflammation and pain following cataract surgery by study day eight, the primary endpoints in the first Phase 3, multi-center, double-masked, vehicle-controlled, parallel-group study.

30 Sep 2014

NIH-funded clinical trial aims to restore vision in people who have lost vision due to IIH

In an NIH-funded clinical trial, led at Saint Louis University by professor of ophthalmology Sophia Chung, M.D., researchers aim to bring sight back to those who have lost vision due to idiopathic intracranial hypertension.

29 Sep 2014

Two genes that cause pediatric glaucoma increases risk of future stroke up to ten times

Every year in Canada about 50,000 people suffer from a stroke, caused either by the interruption of blood flow or uncontrolled bleeding in the brain. While many environmental risk factors exist, including high blood pressure and smoking, stroke risk is also frequently inherited. Unfortunately, remarkably little is known regarding stroke's genetic basis.

26 Sep 2014

FDA approves Contrave extended-release tablets for chronic weight management

Takeda Pharmaceuticals U.S.A., Inc. and Orexigen® Therapeutics, Inc. jointly announced today that the U.S. Food and Drug Administration has approved Contrave® extended-release tablets as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index of 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition.

11 Sep 2014

Glaucoma News and Research

Latest Glaucoma News and Research

Chronic hypertension increases glaucoma risk

Prostaglandin analogue eye drops reduce risk of vision loss in OAG patients

IRIDEX's China distributor secures large tender to supply ophthalmology laser equipment

Eylea receives Health Canada approval for treatment of CRVO and DME

Understanding the genetic basis of glaucoma

Eye screenings of underserved populations reveal one in five has early stage diabetic retinopathy

Leading causes of blindness can be detected by looking at how eyes respond to watching TV

Endothelin gene expression linked to vision loss in premature babies

Hemp Health launches CBD wellness supplements

Tablet screening app can improve eye health outcomes in remote, underserved communities

IRIDEX to host Speakers' Forum program at the American Academy of Ophthalmology

Consultant Live unveils new online sleep disorders educational program for doctors, nurses

IRIDEX's new proprietary disposable delivery device granted U.S. patent

Bausch + Lomb’s sub-micron loteprednol etabonate ophthalmic gel meets primary endpoint

NIH-funded clinical trial aims to restore vision in people who have lost vision due to IIH

Two genes that cause pediatric glaucoma increases risk of future stroke up to ten times

FDA approves Contrave extended-release tablets for chronic weight management

Now, women experiencing morning sickness can benefit from Diclegis drug

Japanese surgeons first to implant InnFocus MicroShunt

BioLight Life Sciences declares first sale of IOPtiMate system in Hong Kong

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Glaucoma News and Research

Latest Glaucoma News and Research

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Newsletters you may be interested in